CA2513143A1 - Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers - Google Patents

Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Download PDF

Info

Publication number
CA2513143A1
CA2513143A1 CA002513143A CA2513143A CA2513143A1 CA 2513143 A1 CA2513143 A1 CA 2513143A1 CA 002513143 A CA002513143 A CA 002513143A CA 2513143 A CA2513143 A CA 2513143A CA 2513143 A1 CA2513143 A1 CA 2513143A1
Authority
CA
Canada
Prior art keywords
cancer
cell
hyaluronan
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513143A
Other languages
English (en)
French (fr)
Inventor
Bryan P. Toole
Suniti Misra
Shibnath Ghatak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2513143A1 publication Critical patent/CA2513143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002513143A 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Abandoned CA2513143A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39290502P 2002-07-01 2002-07-01
US60/392,905 2002-07-01
US45376103P 2003-03-11 2003-03-11
US60/453,761 2003-03-11
PCT/US2003/020918 WO2004003545A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Publications (1)

Publication Number Publication Date
CA2513143A1 true CA2513143A1 (en) 2004-01-08

Family

ID=30003285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513143A Abandoned CA2513143A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Country Status (6)

Country Link
US (2) US8093217B2 (https=)
EP (2) EP2434282A3 (https=)
JP (2) JP5027387B2 (https=)
AU (1) AU2003280471B2 (https=)
CA (1) CA2513143A1 (https=)
WO (1) WO2004003545A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003545A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
EP1768678A4 (en) * 2004-06-30 2009-09-23 Paul L Deangelis METHODS FOR SELECTIVE TREATMENT OF DISEASES BY SPECIFIC GLYCOSAMINOGLYCAN POLYMERS
AU2006249780A1 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2008130373A2 (en) * 2006-10-03 2008-10-30 The Board Of Regents Of The University Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2008140587A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of California Rhamm, a co-receptor and its interactions with other receptors in cancer cell motility and the identification of cancer prognitor cell populations
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
WO2009158040A2 (en) * 2008-06-26 2009-12-30 University Of South Florida Cancer platinum resistance detection and sensitization method
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
WO2014082042A2 (en) 2012-11-25 2014-05-30 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
CN112472699A (zh) * 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof
EP4092045A1 (en) 2016-05-16 2022-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
AU4071197A (en) * 1996-08-16 1998-03-06 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2004003545A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Also Published As

Publication number Publication date
EP2434282A3 (en) 2012-08-22
EP1532434A4 (en) 2009-05-27
JP2005532373A (ja) 2005-10-27
EP2434282A2 (en) 2012-03-28
AU2003280471A1 (en) 2004-01-19
EP1532434A1 (en) 2005-05-25
US20120095277A1 (en) 2012-04-19
US8648047B2 (en) 2014-02-11
US8093217B2 (en) 2012-01-10
JP5027387B2 (ja) 2012-09-19
WO2004003545A9 (en) 2004-04-15
WO2004003545A1 (en) 2004-01-08
US20040229843A1 (en) 2004-11-18
JP2010116410A (ja) 2010-05-27
AU2003280471B2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
US8648047B2 (en) Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
Munshi et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
McDonald et al. Ionizing radiation activates the Nrf2 antioxidant response
Vaisitti et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor
Wei et al. Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer
KR102857853B1 (ko) 암 조직 또는 암 조직과 유사한 조직의 배양 방법
Keysar et al. Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma
Fontana et al. PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma
Kim et al. Combined inhibition of topoisomerase I and poly (ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency
Razonable et al. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines
Deng et al. Inhibition of colorectal cancer aggressiveness by Oleanolic acid through Nur77 degradation
Booth et al. GZ17-6.02 kills PDX isolates of uveal melanoma
Kim et al. Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non–small cell lung cancer
Wang et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines
Kim et al. Hyaluronic acid fuels pancreatic cancer growth
EP3760197B1 (en) Transport protein inhibitor for reducing expression of pd-1
Ma et al. Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin
Szewczyk et al. Optimizing Jasplakinolide delivery in rhabdomyosarcoma cells using pulsed electric fields (PEFs) for enhanced therapeutic impact
Sinha et al. Collagen gel culture of rat mammary tumor cells as an assay system for determination of therapeutic efficacy of chemotherapeutic agents
Yang et al. Discovery of a novel STAT3 inhibitor: A potential application for pancreatic cancer treatment
Liu et al. Calcitonin receptor‐mediated CFTR activation in human intestinal epithelial cells
US20240166702A1 (en) Compositions and methods for treating breast cancer
US20240226234A1 (en) Wnt5a peptides for the treatment of acute myelogenous leukemia
Hampton et al. Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer
Moxley DCLK-1 Regulates Chemotherapy Response in Epithelial Ovarian Cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160704